India Monoclonal Antibodies Market to grow with a CAGR of 10.25%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the India Monoclonal Antibodies Market.
According
to TechSci Research report, “India Monoclonal Antibodies Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, India Monoclonal Antibodies
Market has valued at is anticipated to witness an impressive growth in the
forecast period with a CAGR of 10.25 % through 2029. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
Innovation
in research plays a significant role in driving the demand for Monoclonal
Antibodies (mAbs). Ongoing research leads to the identification of new
therapeutic targets. These targets may be specific proteins, antigens, or cells
associated with diseases. When new targets are discovered, researchers often
explore mAbs to develop precise and effective therapies. Research drives the
development of novel mAbs. Scientists continually work on creating mAbs with
improved specificity, efficacy, and safety profiles. This innovation results in
a broader range of treatment options for various diseases. Research into
personalized medicine and genetic variations in patient populations can
identify individuals who are more likely to respond to specific mAbs. Tailoring
mAb treatments to a patient's unique genetic and molecular profile is a growing
area of research and innovation. Research explores the potential of combining
mAbs with other treatments, such as chemotherapy, radiation therapy, or other
targeted therapies. These combination therapies can enhance treatment outcomes
and reduce side effects. In some cases, diseases, particularly cancers, develop
resistance to existing therapies. Ongoing research aims to develop mAbs that
can overcome this resistance and offer new options for patients.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" India Monoclonal Antibodies Market”
In June 2021, Casirivimab and Indevimab are monoclonal
antibodies designed to target the spike protein of SARS-CoV-2, the virus
responsible for COVID-19. These antibodies have been made available in India
and are specifically engineered to block the virus from attaching to and
entering human cells. This advanced treatment offers protection to individuals
who have tested positive for COVID-19 and are experiencing mild to moderate
symptoms, with the goal of preventing their condition from worsening or necessitating
hospitalization. This single-dose infusion-based therapy can be administered
either intravenously or subcutaneously in a hospital's outpatient setting.
After receiving the antibody infusion, patients are closely monitored for
potential side effects for a few hours. Following this observation period,
patients are allowed to return home for quarantine and are advised to
diligently adhere to COVID-19 isolation protocols.
Safety
and monitoring are critical challenges in the India Monoclonal Antibodies
(mAbs) Market, as they are in any healthcare sector. Ensuring the safety of
patients receiving mAb therapies and monitoring their outcomes is of paramount
importance. One of the key safety concerns with mAbs is the potential for
patients to develop immune responses to the therapy. This immune reaction can
affect the mAb's efficacy and safety. Monitoring immunogenicity and developing
strategies to mitigate its impact are essential. Like any medical treatment,
mAb therapies can lead to adverse events or side effects. Monitoring and
reporting of adverse events are crucial for patient safety and for gathering
data on the safety profile of mAbs. Some mAbs are administered intravenously,
and patients may experience infusion-related reactions, which can range from
mild to severe. Proper monitoring during and after infusion is necessary to
manage these reactions. As mAb treatments may be administered over an extended
period, it's essential to monitor and assess their long-term safety and any
potential cumulative effects. Ensuring that patients adhere to their prescribed
mAb treatment regimens and monitoring their compliance is crucial for both
safety and treatment effectiveness. Individual patient responses to mAbs can
vary. Optimizing the dose and treatment regimen for each patient is important
for safety and efficacy.
India Monoclonal Antibodies Market is segmented
based on Type, Application, Production, Biomanufacturing, End-user, and by
region.
Based on the Application, India Monoclonal
Antibodies Market is segmented into Cancer, Cardiac/Cardiovascular,
Neurological, Others. Neurological disorders encompass a wide range of
conditions affecting the nervous system, including the brain and spinal cord.
These disorders can be neurodegenerative diseases (e.g., Alzheimer's and
Parkinson's), autoimmune disorders (e.g., multiple sclerosis), or conditions
like stroke and neuromuscular disorders. Some neurological disorders are caused
by the immune system mistakenly attacking components of the nervous system.
Monoclonal antibodies can be designed to target and modulate specific immune
responses responsible for these autoimmune neurological disorders. Multiple
sclerosis (MS) is a common autoimmune neurological disorder. Certain mAbs have
been developed to modulate the immune response in MS by targeting specific
immune cells or molecules responsible for the inflammatory and demyelinating
processes in the central nervous system. Neurodegenerative
diseases like Alzheimer's and Parkinson's are characterized by the accumulation
of abnormal proteins or protein aggregates in the brain. Monoclonal antibodies
are being researched as potential treatments to target and clear these
pathogenic proteins or to modulate the inflammatory responses associated with
these diseases.
Based on Region, North India held the largest share in the India Monoclonal Antibodies Market.
The availability of venture capital, private equity, and funding opportunities
in the North Indian region attracts both startups and established companies to
invest in monoclonal antibody research and development. North India often
serves as a preferred location for clinical trials due to its diverse patient
population, which is essential for testing the safety and efficacy of mAb
therapies. The region's strong network of academic institutions, research
centers, and pharmaceutical companies encourages collaborations and
partnerships, accelerating the advancement of mAb-related projects. The North
Indian region, with its large and diverse population, has a high demand for
advanced medical treatments, including mAbs. This demand drives the development
and commercialization of these therapies. The region's connectivity, proximity
to major ports, and transportation infrastructure make it favorable for the
import of critical raw materials and the export of finished mAb products.
Some
of the major companies operating in the India
Monoclonal Antibodies Market include:
- Dr.
Reddy's Laboratories Ltd.
- Bristol
Myers Squibb India Pvt. Ltd.
- Roche
India Pvt. Ltd.
- Intas
Pharmaceuticals Limited
- Merck
India
- Eli
Lilly, and Company (India) Private Limited
- Biocon
Limited
- AstraZeneca
India Pvt. Ltd.
- Pfizer
Limited
Download Free Sample Report
Customers can also request 10% free
customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand for Monoclonal Antibodies.
The growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people
each year, are expected to contribute to a remarkable growth of the India
Monoclonal Antibodies Market in the forecast period," said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based Global
management consulting firm.
India
Monoclonal Antibodies Market by Type (Murine, Chimeric, Humanized, Human), By
Application (Cancer, Cardiac/Cardiovascular, Neurological, Others), By
Production (In vitro, In vivo), By Biomanufacturing (Originator, CMO), By End
Users (Hospitals, Research Laboratories, Others), By
Region, By Competition Forecast
& Opportunities, 2019-2029F has
evaluated the future growth potential of India Monoclonal Antibodies Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in India Monoclonal Antibodies Market.
Contact Us-
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
M: +13322586602
Email: [email protected]
Website: www.techsciresearch.com